CD8A and neoplasm: Although TEXprog cells are crucial for sustaining anti‐tumor immunity and mediating response toward PD‐1/PD‐L1 blockade, defective terminal differentiation of stem‐like CD8+ T cells may limit endogenous anti‐tumor immunity[91] and the efficacy of tumor vaccine.[92] Thus, it is essential to find the optimal balance between sustainability and magnitude of anti‐tumor response mediated by less‐ and more‐differentiated TEX cells, respectively.